文献速递瓣膜外科

65岁及以下患者二尖瓣生物瓣置换:Carpentier-Edwards PERIMOUNT心包瓣的长期结局

Bioprosthetic mitral valve replacement in patients aged 65 years or younger: long-term outcomes with the Carpentier-Edwards PERIMOUNT pericardial valve.
PubMed 文献 · Eur J Cardiothorac Surg · 2018-01-01

本研究评估了148例65岁及以下患者植入Carpentier-Edwards PERIMOUNT二尖瓣生物瓣的长期结果,平均随访8.6±5.5年。10、15、20年无结构性瓣膜毁损(SVD)生存率分别为78±5%、47±7%、19±7%,因SVD再次手术的20年实际风险为44±5%,预期瓣膜耐久性为14.2年。结论认为在该选定人群中,因SVD再次手术的死亡风险低。

要点

  • 65岁及以下患者二尖瓣生物瓣置换后,10年无SVD生存率为78±5%。
  • 20年时因SVD再次手术的实际风险为44±5%,预期瓣膜耐久性为14.2年。
  • 因SVD再次手术无手术死亡。

核心结论

  • 在选定的65岁及以下接受二尖瓣心包生物瓣置换的患者中,预期瓣膜耐久性为14.2年。
  • 因SVD再次手术与低死亡风险相关。

研究设计与样本

  • 回顾性研究,1984年至2010年共148例65岁及以下患者植入148枚Carpentier-Edwards PERIMOUNT二尖瓣生物瓣,前瞻性记录基线临床、围手术期和随访数据。
  • SVD通过严格的超声心动图评估定义。

主要发现

  • 平均随访8.6±5.5年,总计1269瓣膜年。
  • 手术死亡率为2.0%。
  • 晚期死亡51例(线性化率4.0%/瓣膜年)。
  • 10年、15年、20年 actuarial 生存率分别为70±4%、53±6%、31±7%。
  • 10年、15年、20年无SVD actuarial 生存率分别为78±5%、47±7%、19±7%。

关键数值与推荐

  • 10年、15年、20年因SVD无再次手术 actuarial 生存率分别为82±4%、50±6%、25±8%。
  • 竞争风险分析显示20年因SVD取瓣实际风险为44±5%。
  • 该年龄组预期瓣膜耐久性为14.2年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mitral valve replacement using a bioprosthesis remains controversial in young patients because data on long-term outcomes are missing. This study evaluated the long-term results of the PERIMOUNT pericardial mitral bioprosthesis in patients aged 65 years or younger. METHODS: From 1984 to 2010, 148 Carpentier-Edwards PERIMOUNT mitral bioprostheses were implanted in 148 patients aged 65 years or younger. Baseline clinical, perioperative and follow-up data were recorded prospectively. Structural valve deterioration (SVD) was defined by strict echocardiographic assessment. RESULTS: The mean follow-up period was 8.6 ± 5.5 years, for a total of 1269 valve-years. Operative mortality rate was 2.0%. Fifty-one late deaths occurred (linearized rate 4.0% per valve-year). Actuarial survival rates averaged 70 ± 4%, 53 ± 6% and 31 ± 7% after 10, 15 and 20 years of follow-up, respectively. Actuarial freedom from SVD at 10, 15 and 20 years was 78 ± 5%, 47 ± 7% and 19 ± 7%, respectively. Reoperation was associated with no operative mortality. Actuarial freedom from reoperation due to SVD at 10, 15 and 20 years was 82 ± 4%, 50 ± 6% and 25 ± 8%, respectively. Competing risk analysis demonstrated an actual risk of explantation secondary to SVD at 20 years of 44 ± 5%. Expected valve durability was 14.2 years for this age group. CONCLUSIONS: In the selected patients aged 65 years or younger undergoing mitral valve replacement with a pericardial bioprosthesis, the expected valve durability was 14.2 years. Reoperation for SVD was associated with a low risk of mortality.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Bourguignon T, Espitalier F, Pantaleon C, et al. Bioprosthetic mitral valve replacement in patients aged 65 years or younger: long-term outcomes with the Carpentier-Edwards PERIMOUNT pericardial valve. Eur J Cardiothorac Surg. 2018. PMID: 29444229. doi:10.1093/ejcts/ezy029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。